Browsing Tag
Cambridge
30 posts
Stryker invests $400m in CMR Surgical as Versius robot opens new soft-tissue growth market
Stryker invests $400 million in CMR Surgical and gains U.S. rights to Versius. Find out what the robotics alliance could mean for SYK investors.
Raspberry Pi (LSE: RPI) revenue jumps 90% as backlog doubles to 2.6m units
Raspberry Pi delivered record first-half revenue and EBITDA as OEM demand accelerated and its order backlog doubled, although memory inventories pushed net cash lower and gross margin slipped despite stronger profit per board.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.
Fulcrum Therapeutics agrees reverse merger with Slate Medicines and $270m dividend
Fulcrum's $270m dividend and 5% stub hand Slate a Nasdaq listing, but SLTE-1009's PACAP bet must beat CGRP incumbents to justify a $350m valuation.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
UK-backed CuspAI targets semiconductor and energy bottlenecks with $450m round
CuspAI has secured $450 million at a $2.6 billion valuation to connect artificial intelligence, laboratories and manufacturers, but commercial value depends on turning digital candidates into validated materials.
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Akamai stock surges 20% on $1.8bn AI cloud deal: What AKAM investors need to watch next
Wall Street wrote off Akamai as a fading CDN name. One $1.8B cloud deal and 40% Cloud Infrastructure growth just rewrote the entire AKAM thesis overnight.
JuliaHub targets industrial digital twins with $65m Series B and Dyad 3.0 launch
Hardware still moves slowly while software races ahead. JuliaHub’s Dyad 3.0 aims to close that gap with agentic industrial AI.